Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

Completed · Phase 1

Conditions studied: Progressive Supranuclear Palsy (PSP)

In brief

The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

Key facts

Study ID

NCT03413319

Run by

AbbVie

People needed

3

Starts

2018-04-17

Expected to finish

2019-11-20

Last updated by the study team

2019-12-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject completed Study C2N-8E12-WW-104 (NCT02494024)
• Subject was not eligible to enroll in Study M15-562 (NCT02985879)

You may not qualify if…

• Subject weighs less than 35 kg at screening
• Subject has any contraindication or inability to tolerate brain MRI
• Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results

Where it is running

• University of California, San /ID# 170113 — La Jolla, California, United States
• Texas Health Physicians Group /ID# 170112 — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.